SEC Form 4 · accession 0001140361-17-008019
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jay Mazelsky
Officer — Executive Vice President
Period of report
Feb 14, 2017
Accepted (ET)
Feb 16, 2017 · 7:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 14, 2017 | M | 545 | $0.00 | A | 16,190 | D | |
| Common Stock | Feb 14, 2017 | M | 403 | $0.00 | A | 16,593 | D | |
| Common Stock | Feb 14, 2017 | M | 472 | $0.00 | A | 17,065 | D | |
| Common Stock | Feb 14, 2017 | M | 737 | $0.00 | A | 17,802 | D | |
| Common StockF2 | Feb 14, 2017 | F | 719 | $141.60 | D | 17,083 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F9,F3 | $141.60 | Feb 14, 2017 | A | 23,326 | A | — | Feb 13, 2027 | Common Stock | 23,326 | 23,326 | D |
| Incentive Stock Option (right-to-buy)F9,F3 | $141.60 | Feb 14, 2017 | A | 706 | A | — | Feb 13, 2027 | Common Stock | 706 | 706 | D |
| Restricted Stock UnitF9,F4 | — | Feb 14, 2017 | A | 2,295 | A | — | — | Common Stock | 2,295 | 14,452 | D |
| Restricted Stock UnitF9,F5 | — | Feb 14, 2017 | M | 545 | D | — | — | Common Stock | 545 | 13,907 | D |
| Restricted Stock UnitF9,F6 | — | Feb 14, 2017 | M | 403 | D | — | — | Common Stock | 403 | 13,504 | D |
| Restricted Stock UnitF7 | — | Feb 14, 2017 | M | 472 | D | — | — | Common Stock | 472 | 13,032 | D |
| Restricted Stock UnitF9,F8 | — | Feb 14, 2017 | M | 737 | D | — | — | Common Stock | 737 | 12,295 | D |
Explanation of responses
- F1Includes 52 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2016.
- F2Closing price of Issuer's common stock on the NASDAQ market on February 14, 2017.
- F3Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2017.
- F4Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2018.
- F5Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2014. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split").
- F6Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2015 and has been adjusted to reflect the Stock Split.
- F7Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2016 and has been adjusted to reflect the Stock Split.
- F8Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five equal annual installments, beginning February 14, 2017.
- F9Not applicable.